To conduct phase i, II, III or IV contraceptive trials in women, treatment trials of gynecologic conditions such as endometriosis or leiomyomata, and development of research protocols on a task…
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N94020D00015
- Awardee
-
Essential Access Health UEI KNVJQY9UH316
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Task orders
- 2 $412,224 obligated
Award facts
- Opportunity
-
- Contraceptive Development Program NICHD Contraceptive Clinical Trials Network Female Sites Pre-Solicitation · NIHNICHDCDP20201 · Posted May 7, 2019
- Contraceptive Development Program NICHD Contraceptive Clinical Trials Network Female Sites Solicitation · Posted Aug 9, 2019
- Combined order value
- $412,224 Current and potential, with all options
- Last date to order 89% complete
- IDV ceiling 8% used
- $5,000,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 18 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute of Child Health and Human Development awarded an indefinite-delivery contract to Essential Access Health on August 1, 2020, with a ceiling of $5 million to conduct Phase I, II, III, or IV contraceptive trials in women, treatment trials of gynecologic conditions such as endometriosis or leiomyomata, and develop research protocols on a task order basis. This is a multiple-award contract with no set-aside. Performance occurs in Los Angeles, California. The contract runs through July 31, 2027.
Essential Access Health, a non-profit organization, has received two cost-no-fee delivery orders under this IDIQ to date. The first, issued September 28, 2023, for $349,327, tasks the contractor to finalize the protocol, obtain regulatory approval, and commence recruitment and enrollment for the Ovaprene vaginal device clinical trial, with performance in Los Angeles and completion by May 30, 2025. The second, issued August 1, 2020, for $62,896.71, directs the contractor to assist in developing new contraceptive products through protocol review, protocol development, and activities associated with the Contraceptive Clinical Trials Network, with completion aligned to the contract end date of July 31, 2027.
Description
To conduct phase i, II, III or IV contraceptive trials in women, treatment trials of gynecologic conditions such as endometriosis or leiomyomata, and development of research protocols on a task order basis under a seven (7) year indefinite-delivery
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N94020D00015?
75N94020D00015 was awarded to Essential Access Health by National Institute of Child Health and Human Development (National Institutes of Health) on August 1, 2020.
How much is contract 75N94020D00015 worth?
Orders under 75N94020D00015 have obligated $412,224. 75N94020D00015's own ceiling is $5,000,000.
How many orders have been placed under contract 75N94020D00015?
2 orders have been placed under 75N94020D00015, the latest on September 28, 2023.
Who can order from contract 75N94020D00015?
75N94020D00015 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N94020D00015 competed?
The extent of competition for 75N94020D00015 was full and open competition. The government received 18 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV